BAT5906 vs Surabgene lomparvovec
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
BAT5906
Developed by Bio-Thera Solutions
NCT05439629 · Phase 3 · completed
The study randomized 488 participants to BAT5906 or active treatment with Lucentis and masked participants, care providers, and investigators. Its primary outcomes were clinical measures of visual acuity, but the registry does not report whether the comparison was favorable or statistically significant, so the evidence remains limited pending results.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
No aligned efficacy figure on record for this race.
Surabgene lomparvovec
Developed by AbbVie and partners
NCT04832724 · Phase 2 · completed
The study enrolled 60 participants into sequential RGX-314 dose and formulation groups without randomization, blinding, or a comparator arm. Its primary endpoint was the surrogate pharmacodynamic measure of RGX-314 protein concentration, and no primary outcome results are available.
Next expected readout: December 2026 · NCT04704921 (registry estimate)
Reported efficacy
RGX-314 target protein concentration in aqueous humor (At Week 24): Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0 (not_applicable)
Result source: NCT04832724
Results for Age-Related Macular Degeneration
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
BAT5906: no structured comparison results are available for Age-Related Macular Degeneration.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Surabgene lomparvovec
show 4 more results
show 4 more results
show 4 more results
show 4 more results
Available safety results
Surabgene lomparvovec
| Dropout rate | 16.7%Cohort 1 NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more results0%Cohort 2 NCT03066258 · Phase 1/2 · registry result, not featured evidence 0%Cohort 3 NCT03066258 · Phase 1/2 · registry result, not featured evidence 0%Cohort 4 NCT03066258 · Phase 1/2 · registry result, not featured evidence 8.3%Cohort 5 NCT03066258 · Phase 1/2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | —Cohort 1 NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more results—Cohort 2 NCT03066258 · Phase 1/2 · registry result, not featured evidence —Cohort 3 NCT03066258 · Phase 1/2 · registry result, not featured evidence —Cohort 4 NCT03066258 · Phase 1/2 · registry result, not featured evidence —Cohort 5 NCT03066258 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 33.3%Cohort 1 NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more results33.3%Cohort 2 NCT03066258 · Phase 1/2 · registry result, not featured evidence 16.7%Cohort 3 NCT03066258 · Phase 1/2 · registry result, not featured evidence 25%Cohort 4 NCT03066258 · Phase 1/2 · registry result, not featured evidence 33.3%Cohort 5 NCT03066258 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | intraocular inflammation 66.7% retinal haemorrhage 66.7% visual acuity reduced/impairment 50% NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more resultsconjunctival haemorrhage 50% intraocular inflammation 50% retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50% NCT03066258 · Phase 1/2 · registry result, not featured evidence conjunctival haemorrhage 66.7% intraocular inflammation 50% retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50% NCT03066258 · Phase 1/2 · registry result, not featured evidence retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 100% conjunctival haemorrhage 75% retinal thickening 33.3% NCT03066258 · Phase 1/2 · registry result, not featured evidence conjunctival haemorrhage 91.7% retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 91.7% eye irritation 33.3% NCT03066258 · Phase 1/2 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT5906's landscape · Surabgene lomparvovec's landscape